The company said net sales for Q1 2025 rose to $698.0 million, up 0.4%, and organic net sales growth was 2.1%. Proprietary Products sales were $563.0 million, and Contract-Manufactured Products sales were $135.0 million.

1. 01

   The company said net sales for Q1 2025 rose to $698.0 million, up 0.4%, and organic net sales growth was 2.1%. Proprietary Products sales were $563.0 million, and Contract-Manufactured Products sales were $135.0 million.

2. 02

   West Pharmaceutical Services reported net income of $89.8 million for Q1 2025, reported-diluted EPS of $1.23 ($1.55 in the same period last year), and adjusted-diluted EPS of $1.45 ($1.56 in the same period last year). The company said it recorded restructuring-related costs of $17.8 million.

3. 03

   The company said it raised its full-year 2025 net sales outlook to $2.945 billion to $2.975 billion (previously $2.875 billion to $2.905 billion) and its adjusted-diluted EPS outlook to $6.15 to $6.35 (previously $6.00 to $6.20). It said the EPS outlook reflects its estimate of $20 to $25 million in tariff costs.

4. 04

   West Pharmaceutical Services reported operating cash flow of $129.4 million, capital expenditures of $71.3 million, and free cash flow of $58.1 million ($27.6 million in the same period last year) for Q1 2025. The company also said it repurchased 550,281 shares for $133.5 million during the same period.

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.